# BeOne Medicines

> BeOne Medicines, formerly BeiGene, is a global oncology company that discovers, develops, manufactures and commercializes cancer medicines. Brukinsa anchors its blood-cancer business, alongside Tevimbra for solid tumors and Beqalzi for a defined mantle cell lymphoma population; internal clinical operations and manufacturing support its global expansion.

- **Founded:** 2010
- **Headquarters:** Basel, Switzerland
- **Founders:** John V. Oyler (Co-founder, Chairman and CEO), Xiaodong Wang (Co-founder and Scientific Advisory Board Chairman)
- **Products:** BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab), BEQALZI (sonrotoclax), PAMIPARIB (BGB-290), Licensed oncology portfolio in China
- **Notable:** First FDA approval for BRUKINSA in November 2019., ALPINE demonstrated improved progression-free survival versus ibrutinib in relapsed or refractory CLL/SLL., Listed on Nasdaq, Hong Kong Stock Exchange and Shanghai STAR Market.

## Products & services

- **BRUKINSA (zanubrutinib)** — Oral Bruton tyrosine kinase inhibitor for specified B-cell malignancies; first FDA approval in 2019, with CLL/SLL approval in 2023. Indications differ by jurisdiction.
- **TEVIMBRA (tislelizumab)** — PD-1 checkpoint-inhibitor antibody for specified solid tumors; first approved in China in 2019 and first approved by the FDA in 2024. Indications and combinations vary by country.
- **BEQALZI (sonrotoclax)** — BCL-2 inhibitor granted FDA accelerated approval on May 13, 2026 for adults with relapsed or refractory mantle cell lymphoma after at least two systemic therapies, including a BTK inhibitor. Continued approval may depend on confirmatory evidence.
- **PAMIPARIB (BGB-290)** — PARP inhibitor approved in China in 2021 for a defined previously treated BRCA-mutated advanced ovarian, fallopian tube or primary peritoneal cancer population.
- **Licensed oncology portfolio in China** — Commercialization of selected partner medicines, including Amgen’s Xgeva, Blincyto and Kyprolis, under regional agreements.
- **Oncology clinical development pipeline** — Investigational programs include BTK-targeting degraders, antibody-drug conjugates, bispecific antibodies and combination regimens; investigational status does not establish efficacy or approval.

## Achievements

- First FDA approval for BRUKINSA in November 2019.
- ALPINE demonstrated improved progression-free survival versus ibrutinib in relapsed or refractory CLL/SLL.
- Listed on Nasdaq, Hong Kong Stock Exchange and Shanghai STAR Market.
- FY2025 revenue rose 40.2% to US$5.343 billion; GAAP net income was US$286.933 million.
- BEQALZI received FDA accelerated approval in May 2026 for its defined mantle cell lymphoma indication.

## Latest updates

- **2026-10** — On October 19, announced forthcoming solid-tumor portfolio presentations at ESMO 2026, scheduled for October 23-27 in Madrid; these presentations were still upcoming at the research cutoff.
- **2026-08** — Renewed CLL medicine-access partnership through 2028 with The Max Foundation and BeOne Care Foundation.
- **2026-08** — Announced clinical development and selected Asian-market commercialization collaboration with Revolution Medicines.
- **2026-08** — Reported Q2 revenue of US$1.7 billion and BRUKINSA revenue of US$1.2 billion; raised 2026 revenue guidance to US$6.6-6.8 billion.
- **2026-07** — Announced US$300 million Hopewell expansion to add small-molecule manufacturing, bringing total U.S. manufacturing investment commitment above US$1 billion.
- **2026-05** — FDA granted accelerated approval to sonrotoclax, branded BEQALZI, for a specified previously treated mantle cell lymphoma population.
- **2026-05** — FDA issued an untitled letter concerning false or misleading BRUKINSA television advertising, including unsupported quality-of-life implications and presentation of risk information.

## Links

- Website: https://beonemedicines.com/
- LinkedIn: https://www.linkedin.com/company/beonemedicines
- Twitter/X: https://twitter.com/beigeneglobal
- YouTube: https://www.youtube.com/@BeOneMedicines
- Instagram: https://www.instagram.com/beonemedicines/
- Facebook: https://www.facebook.com/BeOneMeds

---

Profile page: https://yespress.io/beone-medicines
Published by YesPress — https://yespress.io
Last updated: 2026-10-22